NeuroDerm’s IPO Comes Up Short

– Israel’s NeuroDerm, which has developed a transdermal drug delivery system for the treatment of Parkinson’s disease, held a less than stellar IPO on the NASDAQ, selling 4.5 million shares More...

Pharmaceutical NeuroDerm Prepares for NASDAQ IPO

NeuroDerm Ltd., an Israeli clinical stage pharmaceutical company which develops drugs for central nervous system (CNS) diseases, announced the launch of its initial public offering of 4.5 million ordinary More...